H1299 Cell Lysates

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Cancers of Non-thoracic Origin With Metastases to the Lungs or PleuraCarcinoma, Non-Small-Cell LungCarcinomasEsophageal Cancer (EsC)Esophageal NeoplasmsEsophagus CancerEsophagus NeoplasmMelanoma

Phase 1

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

TerminatedNCT02054104

National Cancer Institute (NCI)Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Melanoma, Sarcoma +2

Start: 2014-09-03End: 2015-06-15Updated: 2022-01-26

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

SuspendedNCT05642195

National Cancer Institute (NCI)Carcinoma, Non-Small-Cell Lung, Carcinomas, Non-Small Cell Lung Cancer +1

Start: 2026-09-23End: 2035-12-30Target: 30Updated: 2026-09-18

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

WithdrawnNCT05898828

National Cancer Institute (NCI)Esophageal Cancer (EsC), Esophageal Neoplasms, Esophagus Cancer +3

Start: 2024-08-02End: 2024-08-02Updated: 2024-08-05